ducovest

CHGCY:OTO-Chugai Pharmaceuticals Co. Ltd. ADR (Unsponsored) (USD)

COMMON STOCK | Drug Manufacturers—General | OTC Pink

Last Closing

USD 249.23

Change

+11.47 (+4.82)%

Market Cap

USD 18.41B

Volume

9.80K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Chugai Pharmaceutical Co Ltd is engaged in the manufacture, sale, import and export of pharmaceuticals products.

Company Website : http://www.chugai-pharm.co.jp

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-08 )

Largest Industry Peers for Drug Manufacturers—General

ETFs Containing CHGCY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers—General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 34.31% 97% N/A 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.31% 97% N/A 89% A-
Trailing 12 Months  
Capital Gain 95.20% 100% F 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 95.20% 94% A 92% A
Trailing 5 Years  
Capital Gain 284.91% 93% A 92% A
Dividend Return 1.65% 10% F 9% A-
Total Return 286.56% 93% A 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 26.44% 92% A 70% C-
Dividend Return 26.77% 89% A- 69% C-
Total Return 0.34% 17% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 23.27% 42% F 73% C
Risk Adjusted Return 115.08% 94% A 97% N/A
Market Capitalization 18.41B 80% B- 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.